Chief Financial Officer
Henrik Damkjær Simonsen
Henrik Simonsen, Chief Financial Officer, joined Nuevolution in August 2015. He has extensive experience as analyst of pharmaceutical and biotech companies, experience from IPOs of life science companies in Denmark, Sweden, UK and Belgium, and M&A experience from transactions with Nordic life science companies. His most recent position was at SEB, where he was Director, responsible for life science, in SEB Corporate Finance. Prior to that, he was senior analyst at SEB Equities (2004-11). From 1990-2004, he was equity analyst and senior equity analyst at Nordea Securities.
Henrik received his MSc. in Economics from the University of Copenhagen.
Number of shares: 650
Number of warrants: 86,599 warrants series 1 and 3,822 warrants series 2